Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

NIVOREN GETUG-AFU 26

Name: NIVOREN GETUG-AFU 26: Updates and implications
Uploaded: 2019-10-01T00:00:00Z
Duration: 2 min 4 s
Description: Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, speaking on the NIVOREN GETUG-AFU 26 study: the real-world implications of nivolumab in metastatic renal cell carcinoma patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sorry, no posts matched your criteria.

NIVOREN GETUG-AFU 26

Cookie settings